-
公开(公告)号:USD862346S1
公开(公告)日:2019-10-08
申请号:US29641734
申请日:2018-03-23
设计人: David Woodhouse , Kemal Curic , Viet Nguyen
-
公开(公告)号:USD862345S1
公开(公告)日:2019-10-08
申请号:US29641732
申请日:2018-03-23
设计人: David Woodhouse , Kemal Curic , Viet Nguyen
-
公开(公告)号:USD860070S1
公开(公告)日:2019-09-17
申请号:US29632606
申请日:2018-01-09
设计人: David Dewitt , Todd Willing , Max Wolff , Pedro Guarinon
-
公开(公告)号:US10414831B2
公开(公告)日:2019-09-17
申请号:US16178943
申请日:2018-11-02
发明人: Hans Andreasen
IPC分类号: C08B37/02 , C07H3/06 , A61K31/721 , A61K47/26
摘要: The invention relates to an iron oligosaccharide compound with improved stability comprising a hydrogenated oligosaccharide in stable association with ferric oxyhydroxide, the content of dimes saccharide in said hydrogenated oligosaccharide being 2.9% by weight or less, based on the total weight of the hydrogenated oligosaccharide. In further aspects is provided a process for preparing said compound as well as the use of said compound for preparation of a composition for treatment of iron deficiency anaemia.
-
5.
公开(公告)号:US10407488B2
公开(公告)日:2019-09-10
申请号:US15034385
申请日:2014-11-04
IPC分类号: A61K38/36 , C07K14/745 , A61K38/48 , A61K45/06
摘要: The present application generally relates to methods to prevent or treat bleeding and/or hypocoagulation in an individual in need thereof, and compositions for use in such methods. The methods comprise administration of FVa, preferably an APC resistant FVa (such as superFVa), alone or in combination with FVIIa, preferably rhFVIIa (such as NovoSeven® or another FVIIa having enhanced activity or half-life). When administered in combination, FVa and FVIIa elicit a synergistic benefit when used to treat or prevent bleeding or hypocoagulation in subjects in need thereof, e.g., subjects with a genetic disorder such as hemophilia or an acquired bleeding disorder or other condition associated with bleeding or hypocoagulation such as hemorrhagic stroke or shock, trauma, surgery or dysmenorrhea or individuals who produce inhibitory antibodies against procoagulants such as FVIII or FIX or who have been administered an overdose of an anticoagulant drug such as a direct Xa or direct thrombin inhibitor or a Novel Oral Anti-Coagulant (NOAC) or demonstrate unexplained bleeding. Also, the invention relates to the use of a superFVa alone or in combination with FVIIa or other procoagulant or prohemostatic agent to prevent, treat or reverse APC-associated bleeding, e.g., as the result of APC overproduction (such as through serious injury and/or hemorrhagic shock) or APC or other anticoagulant therapy, e.g., in the treatment of inflammatory disorders or sepsis disease.
-
公开(公告)号:USD856027S1
公开(公告)日:2019-08-13
申请号:US29648838
申请日:2018-05-24
申请人: Chih-Yin Chang
设计人: Chih-Yin Chang
-
公开(公告)号:US10370455B2
公开(公告)日:2019-08-06
申请号:US14960973
申请日:2015-12-07
申请人: IMMUNEXT, INC.
发明人: Michael Molloy , Yalin Guo , Jay Rothstein , Michael Rosenzweig
IPC分类号: C07K16/28 , A61K39/395 , C07K16/42 , C07K14/705 , C12N15/113 , A61K39/00
摘要: The receptor for VISTA is identified (VSIG8) as well as the use of this receptor in the identification or synthesis of agonist or antagonist compounds, preferably antibodies, polypeptides and fusion proteins which agonize or antagonize the effects of VSIG8 and/or VISTA and/or the VSIG8/VISTA binding interaction. These antagonists may be used to suppress VISTA's suppressive effects on T cell immunity, and more particularly used in the treatment of cancer, or infectious disease. These agonist compounds may be used to potentiate or enhance VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity, such as in the treatment of autoimmunity, allergy or inflammatory conditions. Screening assays for identifying these agonists and antagonist compounds are also provided.
-
8.
公开(公告)号:US10364295B2
公开(公告)日:2019-07-30
申请号:US15429276
申请日:2017-02-10
发明人: Myron Arlen , J. Andrew Bristol , Ariel Hollinshead , Kwong Tsang
IPC分类号: C07K16/30 , A61K39/395 , A61K45/06 , C07H21/04 , A61K39/00
摘要: Purified or highly pure recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens (CPAA), along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to said nucleic acids and uses for said sequences are provided.
-
公开(公告)号:USD854204S1
公开(公告)日:2019-07-16
申请号:US29629270
申请日:2017-12-12
设计人: Ming-Hung Ting , Chih-Wei Shih
-
10.
公开(公告)号:US10352394B2
公开(公告)日:2019-07-16
申请号:US15468996
申请日:2017-03-24
发明人: Yuri A. Karpenko , Sheri Callies , David Allen , Chad Doorlag
摘要: An elastomeric bushing for vehicle suspension includes inner and outer metal tubes, an elastomeric material between the tubes, and one or more bundles of woven wires (ropes or cables) in entangled or mesh form wherein at least a portion of the wires contact at least one of the tubes. The bushing has enhanced thermal conductivity via metal-to-metal contact and improved damping capacity to reduce heat buildup inside the material upon cyclic loading and unloading. The metallic wire rope, metallic wire ropes or wire mesh are embedded in the elastomeric material during injection molding where the ends of the wire ropes are attached to the opposing side walls of the inner and outer metal tubes or are spaced apart from the opposing side walls for tunability and to thereby enable a more effective dissipation of the heat generated inside the elastomeric bushing during its usage into the kinematically connected suspension members.
-
-
-
-
-
-
-
-
-